21 April 2023>: Original Paper
Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation
Chih-Hsien Cheng ABCDE , Hao-Chien Hung BC , Jin-Chiao Lee BC , Yu-Chao Wang CD , Tsung-Han Wu CD , Chen-Fang Lee ABC , Ting-Jung Wu BC , Hong-Shiue Chou BC , Kun-Ming Chan BC , Wei-Chen Lee ABCD*DOI: 10.12659/AOT.938731
Ann Transplant 2023; 28:e938731
Table 1 Patient characteristics.
Age (years), median (range) | 54 (35–67) |
Sex, male/female, n | 15/2 |
MELD, median (IQR) | 19 (9–27) |
Indication for transplantation, n (%) | |
Hepatic failure | 5 (29.4) |
Complications of liver cirrhosis | 4 (23.5) |
HCC | 8 (47) |
Pre-transplant comorbidity, n (%) | |
HTN | 4 (23.5) |
DM | 3 (17.6) |
Type of transplant, n (%) | |
LDLT | 10 (58.8) |
DDLT | 4 (23.5) |
SLT | 3 (17.7) |
HBeAg positive, n (%) | 4 (23.5) |
Quantitative HBsAg (IU/ml), median (IQR) | 243 (43–153332) |
HBV DNA (IU/ml), median (IQR) | 182 (20–68330000) |
HCV coinfection, n (%) | 1 (5.9) |
Duration of TDF treatment (days), median (range) | 1137 (579–1639) |
HBsAg persistence, n (%) | 7 (41.1) |
HBV recurrence, n (%) | 6 (35.3) |
Therapy, naïve/with previous therapy/switch after recurrence, n | 6/5/6 |
MELD – Model For End-Stage Liver Disease; HCC – hepatocellular carcinoma; HTN – hypertension; DM – diabetes mellitus; LDLT – living donor liver transplantation; DDLT – deceased donor liver transplantation; SLT – split liver transplantation; IQR – interquartile range; HBeAg – hepatitis B e antigen; HBsAg – hepatitis B surface antigen; HBV – hepatitis B virus; HCV – hepatitis C virus; HCC – hepatocellular carcinoma; TDF – tenofovir disoproxil fumarate. |